COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02393625
Recruitment Status : Active, not recruiting
First Posted : March 19, 2015
Last Update Posted : January 6, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients

Condition or disease Intervention/treatment Phase
ALK-positive NSCLC Drug: Ceritinib (LDK378) Drug: Nivolumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
Actual Study Start Date : May 27, 2015
Estimated Primary Completion Date : June 8, 2021
Estimated Study Completion Date : June 8, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dose Escalation Drug: Ceritinib (LDK378)
Drug: Nivolumab
Experimental: Dose Expansion Drug: Ceritinib (LDK378)
Drug: Nivolumab

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) and/or Recommended Dose for Expansion [ Time Frame: Study Day 42 (6 weeks) ]
  2. Overall response rate (ORR) [ Time Frame: 24 Weeks ]
    ORR (complete response (CR)+ partial response (PR)) per RECIST 1.1 as assessed by investigator

Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: 24 weeks ]
  2. Disease Control Rate (DCR) [ Time Frame: 24 weeks ]
  3. Time to Response (TTR) [ Time Frame: 24 weeks ]
  4. Progression Free Survival (PFS) [ Time Frame: 24 weeks ]
  5. Overall survival (OS) [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK rearrangement
  • Stage IIIB or IV NSCLC or relapsed locally advanced or metastatic NSCLC
  • Presence of at least one measurable lesion as defined by RECIST 1.1
  • Patients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade ≤1 (CTCAE v 4.03). Patients with grade ≤ 2 peripheral neuropathy or any grade of alopecia, fatigue, nail changes or skin changes are allowed to enter the study
  • Patient has a WHO performance status 0-1

Exclusion Criteria:

  • Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years
  • Patients with an active, known or suspected autoimmune disease
  • Unable or unwilling to swallow tablets or capsules
  • Patient has other severe, acute, or chronic medical conditions including uncontrolled diabetes mellitus or psychiatric conditions or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02393625

Layout table for location information
United States, Arizona
Mayo Clinic - Arizona
Scottsdale, Arizona, United States, 85259
United States, Massachusetts
Massachusetts General Hospital Thoracic Oncolgoy
Boston, Massachusetts, United States, 02115
United States, Pennsylvania
Fox Chase Cancer Center StudyCoordinator
Philadelphia, Pennsylvania, United States, 19111
Australia, Victoria
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Novartis Investigative Site
Leuven, Belgium, 3000
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z6
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Modena, MO, Italy, 41124
Novartis Investigative Site
Rotterdam, Netherlands, 3015 GD
Novartis Investigative Site
Singapore, Singapore, 169610
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT02393625    
Other Study ID Numbers: CLDK378A2120C
First Posted: March 19, 2015    Key Record Dates
Last Update Posted: January 6, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
NSCLC, ALK-positive
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action